Farmas USA

NAVB

EPS of ($0.05), $0.02 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $2.1 million versus the consensus estimate of $3.3 million.
The Company reiterates its 2015 Lymphoseek product revenue estimate of $10 million to $12 million. Additionally, margins on Lymphoseek product sales are expected to approach and possibly exceed 80% in the coming quarters. The Company also expects, following completion of the partnering activities for NAV4694, that cash operating expenses on a quarterly basis will continue to decrease to the point necessary for the Company to achieve its goals of cash flow breakeven from operations. This guidance excludes therapeutic-related research and development costs for the Manocept platform which are expected to be funded separately by Macrophage Therapeutics, Inc.

Navidea secures an expensive $60M loan

Navidea Biopharmaceuticals (NYSEMKT:NAVB) secures a $60M loan from CRG which it will use to retire its debt from Oxford Finance, support the commercialization of Lymphoseek and general corporate purposes.
Under the terms of the loan, Navidea will receive an initial $50M for a term of six years, the first four interest-only, at a 14% interest rate. An additional $10M will be available under certain conditions. After paying off the Oxford debt, the company will have $18M in new capital.
In conjunction with the CRG financing, Navidea amends its existing line of credit with Platinum-Montaur Life Sciences that will allow it to remain in place in a subordinated position to the CRG loan. Platinum may convert the company's $7.7M debt into common stock if the average price exceeds $2.53 per share for 10 consecutive trading days. Today's close was $1.35.

CYTX

EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $900 thousand versus the consensus estimate of $2.44 million

Ascendiant Capital initiated coverage on Cytori Therapeutics with a Buy rating and a price target of $1.25.

Buen arranque de nuestras NYMX

ARNA

2 actualizaciones de PO y dos artículos del Osborne.

-WallachBeth reiterated Arena Pharm (ARNA) coverage with Buy and target $6 (previo 8$

-BMO Capital analyst Jim Birchenough reiterated a Market Perform rating and $9 price target, with BELVIQ trends remaining underwhelming.

Birchenough commented, "We are maintaining our Market Perform rating on the shares of ARNA following review of 1Q15 operating results. BELVIQ launch trends remain modest and efforts to stimulate growth so late in the launch cycle are unlikely to be successful, in our view. We believe that pipeline development remains critical but ARNA appears behind competition in developing oral alternatives to injectable drugs for autoimmune disease and PAH and features of differentiation appear unclear."

Arena Beats The Street On A Mixed Bag
http://seekingalpha.com/article/3173376-arena-beats-the-street-on-a-mixed-bag

Los índices no acompañan. Pero a algunas no les importa, PTIE +85,05%, uffff

http://www.streetinsider.com/Corporate+News/Pain+Therapeutics+%28PTIE%29+Reports+Results+of+Human+Abuse+Potential+Study+with+REMOXY/10549644.html?si_client=intbro

THLD

Aguantarlas ¿eh?, la noticia merece más que un +14%.

La única verdad verdadera en este mundo es que hay que tener paciencia....
Las PTIE; por ejemplo, lllevaban desde octubre del año pasado, cuando se pegaron el hostión, sin subir....
Y hoy, ya veis....
El que comprara a raíz de la caída, en menos de un año, un 150%....
Yo, como ovy saltado de flor en flor, pues así me va, que últimamente no pillo una....

PTIE

Edito: que triste saberse la teoría al dedillo y ser incapaz de llevarla a la práctica...jajajaj